VK2735 and retatrutide are two of the most closely watched investigational obesity peptides currently in development, and they're frequently mentioned in the same breath as possible successors to today's approved GLP-1 drugs. Both remain unapproved, in-development compounds, but they differ in mechanism, sponsor, and how far along their development programs are.

What Each One Is

VK2735, developed by Viking Therapeutics and covered in more detail in this site's dedicated VK2735 guide, is a dual agonist targeting both the GLP-1 and GIP receptors, the same two-receptor mechanism used by Eli Lilly's approved drug tirzepatide. Viking is developing VK2735 in both injectable and oral formulations, a dual-format strategy this site's coverage of Viking's Phase 3 program discusses in more detail. Retatrutide, also developed by Eli Lilly and covered in this site's retatrutide guide, is a triple agonist, adding a third receptor target, the glucagon receptor, on top of GLP-1 and GIP activity. That third mechanism is the basis for retatrutide's classification as a "triple agonist" rather than a dual agonist.

Mechanism: Why a Third Receptor Matters, in Theory

The rationale for adding glucagon receptor activity, as retatrutide does, is that glucagon signaling is associated with increased energy expenditure in preclinical models, on top of the appetite-suppressing effects GLP-1 and GIP agonism already provide. In principle, that could translate into greater weight loss than a dual-agonist mechanism alone. In practice, cross-drug comparisons at the mechanistic level don't reliably predict real-world clinical outcomes, and the only way to know whether a third receptor target produces meaningfully better results is a completed, adequately powered human trial, ideally one that compares the drugs directly rather than across separate trials with different populations and designs.

Where Each Program Stands

Retatrutide's TRIUMPH program has moved further through Phase 3, with this site's earlier coverage of the TRIUMPH-1 trial reporting weight-loss results in the range of 30% in a Phase 3 obesity study, and later TRIUMPH-2 and TRIUMPH-3 trials reporting further results in diabetes and cardiovascular-risk populations. VK2735 has advanced into Phase 3 for its oral obesity program, following earlier Phase 2 results, but its Phase 3 data package is, as of this writing, less mature than retatrutide's. Neither drug has completed the full regulatory review process, and no head-to-head trial directly comparing VK2735 and retatrutide in the same study has been reported.

What's Not Yet Known

Because both compounds remain investigational, several things simply aren't established yet for either one: a final approved dose, a complete long-term safety profile beyond the duration of their respective trials, and, most importantly for anyone comparing them, real-world effectiveness and safety outside a closely monitored clinical trial population. Cross-trial comparisons, which is what most "which drug wins" commentary online is actually doing, are inherently less reliable than a genuine head-to-head study, since different trials enroll different patient populations and use different protocols. This site's guide on placebo-controlled trials and its guide on why sample size matters both explain why that distinction is more than a technicality.

The Bottom Line

VK2735 and retatrutide represent two different approaches, dual versus triple receptor agonism, to the same broad goal of improving on existing GLP-1 therapies, and both have shown encouraging Phase 2 or Phase 3 results in their own trials. Neither is FDA-approved, neither has completed the regulatory process, and no direct comparative trial exists between them. Patients interested in either compound, or in how they might eventually compare to approved options like semaglutide and tirzepatide, should talk to a licensed physician about currently approved treatments rather than treating investigational trial data as a basis for near-term decisions.